ReviewCell proliferation2015
Signalling pathways involved in the process of mesenchymal stem cells differentiating into hepatocytes.
Review in Cell proliferation, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 35 citations in OpenAlex.
- Unraveling the Exosome-miR-133a Axis: Targeting TGF-β Signaling via WJ-MSC-Derived Exosomes for Anti-Fibrotic Therapy in Liver Fibrosis.Iranian biomedical journal · 2024Article
- Leveraging stem cells to combat hepatitis: a comprehensive review of recent studies.Molecular biology reports · 2024Review
- Schisandrin B promotes hepatic differentiation from human umbilical cord mesenchymal stem cells.iScience · 2024Article
- Mechanisms of Action of Mesenchymal Stem Cells in Metabolic-Associated Fatty Liver Disease.Stem cells international · 2023Review
- Mesenchymal stromal cells (MSCs) and their exosome in acute liver failure (ALF): a comprehensive review.Stem cell research & therapy · 2022Review
- Current Status and Challenges of Human Induced Pluripotent Stem Cell-Derived Liver Models in Drug Discovery.Cells · 2022Review
- Article
- Genetic modification by overexpression of target gene in mesenchymal stromal cell for treating liver diseases.Journal of molecular medicine (Berlin, Germany) · 2021Review
- Advancements in stem cell-derived hepatocyte-like cell models for hepatotoxicity testing.Stem cell research & therapy · 2021Review
- A time-resolved multi-omic atlas of the developing mouse liver.Genome research · 2020Article
- Pre-treatments enhance the therapeutic effects of mesenchymal stem cells in liver diseases.Journal of cellular and molecular medicine · 2020Review
- ATSC transplantation contributes to liver regeneration following paracetamol-induced acute liver injury through differentiation into hepatic-like cells.American journal of stem cells · 2020Article
- Human amniotic membrane conditioned medium inhibits proliferation and modulates related microRNAs expression in hepatocarcinoma cells.Scientific reports · 2019Article
- Remodeling of Glycosaminoglycans During Differentiation of Adult Human Bone Mesenchymal Stromal Cells Toward Hepatocytes.Stem cells and development · 2019Article
- Zebularine Promotes Hepatic Differentiation of Rabbit Bone Marrow Mesenchymal Stem Cells by Interfering with p38 MAPK Signaling.Stem cells international · 2018Article
- Mesenchymal Stem Cells after Polytrauma: Actor and Target.Stem cells international · 2016Review
- Promising Therapy Candidates for Liver Fibrosis.Frontiers in physiology · 2016Review
- Stem Cells and Regenerative Medicine: Myth or Reality of the 21th Century.Stem cells international · 2015Review
- Sepsis: From Pathophysiology to Individualized Patient Care.Journal of immunology research · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
End-stage liver disease can be the termination of acute or chronic liver diseases, with manifestations of liver failure; transplantation is currently an effective treatment for these. However, transplantation is severely limited due to the serious lack of donors, expense, graft rejection and requirement of long-term immunosuppression. Mesenchymal stem cells (MSCs) have attracted considerable attention as therapeutic tools as they can be obtained with relative ease and expanded in culture, along with features of self-renewal and multidirectional differentiation. Many scientific groups have sought to use MSCs differentiating into functional hepatocytes to be used in cell transplantation with liver tissue engineering to repair diseased organs. In most of the literature, hepatocyte differentiation refers to use of various additional growth factors and cytokines, such as hepatocyte growth factor (HGF), fibroblast growth factor (FGF), epidermal growth factor (EGF), oncostatin M (OSM) and more, and most are involved in signalling pathway regulation and cell-cell/cell-matrix interactions. Signalling pathways have been shown to play critical roles in embryonic development, tumourigenesis, tumour progression, apoptosis and cell-fate determination. However, mechanisms of MSCs differentiating into hepatocytes, particularly signalling pathways involved, have not as yet been completely illustrated. In this review, we have focused on progress of signalling pathways associated with mesenchymal stem cells differentiating into hepatocytes along with the stepwise differentiation procedure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.